ASH 2025 ANALYST AND INVESTOR EVENT Our goal is to develop transformative therapies to extend and improve the lives of patients with cancer December 8, 2025 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, expectations regarding the combinability and therapeutic potential of ziftomenib with other th ...

Paramount's $30 all-cash offer provides greater value and certainty to WBD shareholders December 8, 2025 Disclaimer This presentation is provided for informational purposes only and for no other purpose. Certain information contained herein has been obtained from published sources prepared by third parties that Paramount Skydance Corporation ("Paramount") believes to be reliable. Moreover, certain information in this presentation is based on assumptions, estimates and other factors that were available to Pa ...

Home BancShares Announces Acquisition of Mountain Commerce Bancorp, Inc. FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements which include, but are not limited to, statements, estimates and projections about the benefits of the business combination transaction involving Home BancShares, Inc. ("HOMB") and Mountain Commerce Bancorp, Inc. ("MCBI"), including the combined company's future financial condition, operating results, plans, expectations, goals and outlook for the future. ...

Financial Status & Milestones - Theravance Biopharma had approximately $333 million in cash with no debt and expects to remain at similar levels in Q4 2025 [7] - The company anticipates $175 million in near-term milestones based on TRELEGY and YUPELRI sales [7] - Theravance Biopharma has a 35% U S profit share with Viatris for YUPELRI, with IP protection into 2039 [7] Ampreloxetine & CYPRESS Trial - Ampreloxetine targets approximately 40,000 underserved patients in the U S with symptomatic nOH due to MSA [7] - The Phase 3 CYPRESS trial completed enrollment in Q3 2025, with topline data expected in Q1 2026 [7] - In a REDWOOD pre-specified MSA subgroup analysis (n=40), the greatest difference was observed in the 6-item OHSA composite score [48, 51] - Approximately 70-80% of patients with MSA will develop nOH in their lifetime, and despite treatment with available pressor agents, 68% remain symptomatic [30] Commercial Opportunity - The U S market includes approximately 40,000 MSA patients with nOH [7, 83, 96] - Only approximately 34% of patients are currently treated, indicating a significant unmet need [84] - The average launch price for chronic neurology therapies is approximately $333,000 [111]

Transformational Utica Shale Acquisition Infinity Acquires Antero's Ohio Assets December 2025 Transformational Acquisition in Core of Utica Shale Transformational Acquisition in Ohio Utica Shale • Highly contiguous acreage improves long lateral well development and adds high quality inventory across all phase windows, improving overall break-evens CAPTURES VERTICAL INTEGRATION BENEFITS THROUGH ACQUIRED MIDSTREAM ASSETS INR to acquire undivided 51% interest of a high growth, high-return acquisition adjacent ...

Aura Day 2025 D E C E M B E R 2 0 2 5 To find, mine and provide the most important and essential ores that allow the world and mankind to create, innovate and prosper. Aura Day team Seasoned Management Team Glauber Luvizotto Isabela Dumont Head People, Communications & Sustainability Natasha Utescher Head of IR and Treasury Frederico Silva Director of Operations Aura Borborema, Brazil Francisco do Carmo Director of Operations Aura Minosa, Honduras Pitágoras Costa Director of Projects and Construction Richar ...

Antero Resources (NYSE: AR) Legal Disclaimer This presentation includes "forward-looking statements." Such forward-looking statements are subject to a number of risks and uncertainties, many of which are not under AR's control. All statements, except for statements of historical fact, made in this presentation regarding activities, events or developments AR expects, believes or anticipates will or may occur in the future, such as those regarding our financial strategy, future operating results, financial po ...

Disclaimer About Forward-Looking Statements & Third-Party Sources INVESTOR PRESENTATION This presentation (this "Investor Presentation") is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential transaction (the "Transaction") between ContextLogic Holdings Inc., and its subsidiaries (the "Company"), US Salt Parent Holdings, LLC and its subsidiaries ("US Salt"), affiliates of Abrams Capital Management, L.P. ("Abra ...

Strategic Transactions - Antero Resources (AR) is acquiring HG Energy in the core Marcellus Shale and divesting non-core Utica assets[6, 7] - AR is acquiring HG Energy's upstream business for $2.8 billion plus hedge book, and Antero Midstream (AM) is acquiring HG Energy's midstream business for $1.1 billion[10] - AR is divesting upstream assets in Utica for $800 million, and AM is divesting midstream assets in Utica for $400 million[10] HG Acquisition - The HG Acquisition is expected to add approximately 400 additional locations in the Marcellus Shale core, with 75% being liquids-rich[11, 44] - The acquisition is projected to provide ~$950 million in identified synergies[11] - The acquisition is expected to reduce the cost structure by ~$0.25/Mcfe and increase margins by $0.15 to $0.20 per Mcfe[12] - The acquisition is expected to be 30%+ accretive to operating cash flow, free cash flow, and NAV per share metrics[12, 28] - The acquisition is fully financed and expected to be paid off by 2028 through a combination of AR Free Cash Flow, proceeds from the Utica divestiture, and hedged Free Cash Flow of the acquired assets[13] Pro Forma Outlook - Pro forma production outlook for 2027 is projected to be between 4,400 and 4,500 MMcfe/d[15] Utica Divestiture - The Utica divestiture is expected to generate $800 million in proceeds[10] - The Utica divestiture is expected to have a 2026E Free Cash Flow of ~$55 million[9] Antero Midstream (AM) - AM is acquiring HG Midstream for $1.1 billion and divesting Utica Midstream for $400 million[10, 40] - HG Midstream acquisition is expected to add >400 dedicated locations (75% liquids)[42, 44] - HG Midstream has ~900 MMcf/d of throughput[41]

Business Transformation & Strategy - Ingevity is simplifying its business by exiting Industrial Specialties, Advanced Polymer Technologies (APT), and Road Markings [11, 12] - The company is establishing "New Ingevity" with two core businesses: Performance Materials and Pavement Technologies [12] - New Ingevity will leverage strong cash flow and divestiture proceeds to invest in organic growth, reduce debt, and return capital to shareholders [11] Financial Performance & Outlook - Pro Forma 2025E Revenue for New Ingevity is approximately $900 million [14] - Pro Forma 2025E EBITDA is approximately $335 million, with an EBITDA margin of approximately 37% [14] - The company expects to generate over $200 million of free cash flow per year in 2026 and 2027 [71] - New Ingevity projects 2027E Revenue of $940-980 million and EBITDA of $350-370 million, resulting in an EBITDA Margin of 36-39% [61] - The company aims to maintain a leverage target of 2 to 2.5x [71] Segment Specifics - Performance Materials expects 2025E revenue of approximately $600 million with EBITDA margins exceeding 50% [27] - Pavement Technologies expects 2025E revenue of approximately $300 million with EBITDA margins of 33% [49] Capital Allocation - The company plans to use divestiture proceeds to repurchase approximately $300 million of shares over the next 2 years [75]